Results from an updated BYLieve Cohort A analysis demonstrate the ongoing benefit of alpelisib plus fulvestrant in patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer whose disease progressed on or after treatment with a CDK4/6 inhibitor plus an aromatase inhibitor.1 This evidence concerns the gene ERBB2 and breast carcinoma.